Palisade Bio (PALI) Operating Income Growth (1y) (2011 - 2026)
Palisade Bio (PALI) Operating Income Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,071.81 Bn | - | -24.89% |
| 2 | Nanobiotix | 1,925.70 Bn | 1,925.64 Bn | - | - |
| 3 | Akari Therapeutics | 1,062.88 Bn | 1,062.88 Bn | - | - |
| 4 | BeOne Medicines | 469.09 Bn | 464.29 Bn | 1.35 Bn | 2,150.96% |
| 5 | Vertex Pharmaceuticals | 123.09 Bn | 115.84 Bn | 2.59 Bn | 80.62% |
| 6 | Regeneron Pharmaceuticals | 70.32 Bn | 61.57 Bn | 3.31 Bn | 8.65% |
| 7 | Belite Bio | 63.36 Bn | 63.36 Bn | - | - |
| 8 | Argenx Se | 55.90 Bn | 50.71 Bn | 1.41 Bn | 145.20% |
| 9 | Alnylam Pharmaceuticals | 37.69 Bn | 34.68 Bn | 959.66 Mn | 1,386.07% |
| 10 | Palisade Bio | 415.13 Mn | 282.51 Mn | - | -365.28% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -365.28% |
| Dec 31, 2025 | -195.12% |
| Sep 30, 2025 | 18.68% |
| Jun 30, 2025 | 32.49% |
| Mar 31, 2025 | 37.11% |
| Dec 31, 2024 | -7.23% |
| Sep 30, 2024 | 4.90% |
| Jun 30, 2024 | -16.68% |
| Mar 31, 2024 | -45.24% |
| Dec 31, 2023 | 18.04% |
| Sep 30, 2023 | 14.39% |
| Jun 30, 2023 | -1.04% |
| Mar 31, 2023 | 34.95% |
| Dec 31, 2022 | 4.44% |
| Sep 30, 2022 | -46.32% |
| Jun 30, 2022 | 89.13% |
| Mar 31, 2022 | -98.98% |
| Dec 31, 2021 | -24.10% |
| Sep 30, 2021 | -66.08% |
| Jun 30, 2021 | -1,684.79% |